Compare CSX Corporation (CSX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Incyte Corporation — how do they compare? CSX Corporation trades at $50.48 (market cap $92.77B), while Incyte Corporation trades at $120.38 (market cap $24.48B). The key difference: CSX Corporation is far larger — about 3.8× Incyte Corporation's market cap, and CSX Corporation pays a 1.12% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CSX | INCY | |
|---|---|---|
Market Cap | $92.77B | $24.48B |
Sector | Industrials | Health |
52-Week High | $53.21 | $129.93 |
52-Week Low | $32.05 | $81.66 |
Enterprise Value | $110.74B | $19.98B |
Dividend Yield | 1.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $50.09, down slightly by 0.06% today, with a neutral technical signal. Recent Q2 2026 earnings beat expectations with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and improved margins. Analyst consensus is bullish with a $52.57 price target, supported by strong cash flow trends and a 58.69% buy rating from coverage.
The outlook is positive due to volume growth and cost controls, but risks include fuel cost pressures and competitive freight markets. With a P/E of 29.05 above industry averages, the stock offers growth potential if earnings momentum continues, though high debt levels warrant monitoring.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
